Wyeth Seeks Approval To Launch 2 Drugs In Japan By 2007 End (Japan)
This article was originally published in PharmAsia News
Executive Summary
Wyeth is seeking marketing approval to introduce two prescription drugs in Japan. The company will file a new drug application with the Japanese government for Tygacil and Viviant by the end of this year. Viviant is used for osteoporosis, while Tygacil is used to treat pneumonia and other infections. The new drug launches are part of Wyeth's aim to raise sales in Japan to $1 billion by 2010, nearly double that of 2006. (Click here for more - May Require Paid Subscription
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.